Advanced Flower Capital Needs Steadier Originations To Back Up Its NAV Recovery Story

Advanced Flower Capital spent last quarter convincing investors that its transition away from a pure cannabis lender is working. Net asset value per share has climbed three quarters in a row, from $7.46 to $8.25, the distribution is back, and legacy loan recoveries are finally turning into cash. Yet the stock trades near $2.99, roughly a third of that book value. When the company reports before the bell on November 5, the question is whether core lending income can start doing the heavy lifting that one-time items and recoveries have done so far.

The Street expects earnings of $0.16 per share on revenue of $9.1 million. That compares with $0.13 and $8.2 million a year ago, implying growth of about 23% on the bottom line and roughly 11% on the top. The more telling comparison is sequential. Last quarter's reported $0.23 included valuation gains, while net investment income was $0.15 per share after a $1.5 million Bloom exit fee from the prior period did not recur. A $0.16 estimate therefore assumes a modest step up in recurring income, not a repeat of episodic boosts. Management offers little numeric guidance, so the bar is set mainly by the portfolio math.

That math depends on deployment. Fundings fell from about $80 million in the first quarter to just $17 million in the second, and management warned that deal flow would stay lumpy. Revenue rising from $8.7 million to $9.1 million requires the $290 million, 100% first-lien book yielding 13.2% to grow or at least hold its earning assets. The $7 million commitment to a Northeast behavioral health platform, with $3.1 million funded at close, offers early evidence that the healthcare push is real, and new co-investment relief alongside TCG affiliates should open the door to larger deals. A visible conversion of the $1.3 billion pipeline into funded loans would validate the pivot. Another quarter of thin originations would suggest the earnings base is drifting rather than building.

The legacy cannabis book is the other swing factor. The Debbie workout has produced $58 million in cumulative recoveries, and a binding $12.5 million sale of two assets, with about 80% flowing to the company and a $2 million nonrefundable deposit in hand, should be close to resolution. DMA sold two of three dispensaries after the quarter ended. Confirmation that these proceeds arrived on schedule, and that the cash is being recycled into income-producing loans, would support further NAV gains. Justice Grown is the counterweight. That loan defaulted at its May maturity and is now in foreclosure and litigation, so any markdown there could offset progress elsewhere. Federal medical rescheduling adds optionality on recoveries but is not yet a cash event.

Sentiment has warmed considerably. Readings have moved from deeply bearish ahead of the last report to only mildly negative now, and the shares have gained about 5% since then while the S&P 500 slipped slightly. Still, the stock sits only marginally above its 200-day moving average and closer to the bottom of its post-earnings range of $2.82 to $3.69, which hints that investors remain unconvinced. The buyback, executed at $3.29 last quarter with $2.2 million left, becomes even more accretive at current prices, and the pace of repurchases will signal how management views that discount.

The distribution of $0.05 is covered three times over, so it is not in question. What matters is whether this report shows recurring interest income rising on new loans while legacy recoveries keep NAV moving higher. If both happen, the discount to book looks increasingly hard to justify. If originations stall and Justice Grown forces a writedown, the recovery narrative will look more dependent on one-offs than management suggested.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.